Pharsight

Drugs that contain Inotersen Sodium

1. Tegsedi patents expiration

TEGSEDI Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7015315 AKCEA THERAPS Gapped oligonucleotides
Mar, 2023

(11 months ago)

US7101993 AKCEA THERAPS Oligonucleotides containing 2′-O-modified purines
Sep, 2023

(5 months ago)

US8101743 AKCEA THERAPS Modulation of transthyretin expression
Apr, 2025

(1 year, 30 days from now)

US9061044 AKCEA THERAPS Modulation of transthyretin expression
Apr, 2031

(7 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9399774 AKCEA THERAPS Modulation of transthyretin expression
Apr, 2031

(7 years from now)

US8697860 AKCEA THERAPS Diagnosis and treatment of disease
Apr, 2031

(7 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Oct 5, 2025

Market Authorisation Date: 05 October, 2018

Treatment: Treatment of polyneuropathy of hereditary transthyretin amyloidosis

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

TEGSEDI family patents

Family Patents